In emerging markets, ABT logged 14% YoY constant-currency sales growth in 2Q12: http://finance.yahoo.com/news/abbott-reports-strong-second-quarter-114400940.html This includes sales from the entire company, i.e. both the Established Products unit and the Pharma unit that will become AbbVie.